Jeff Walsh Email Address

Venture Partner

bluebird bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.

More than 30 years of experience with high growth, public and private life sciences companies including Chief Financial Officer, Chief Operating Officer & Chief Strategy Officer roles with responsibility for strategy, finance, business development, program leadership, commercial development, operations and legal functions. - Joined Third Rock Ventures in 2022 as a Venture Partner with the hope of helping to build some of the next great healthcare breakthrough companies. - Joined bluebird in 2011 with broad operations, business development, commercial development, program management, strategy and global finance responsibilities. As COO/CFO, helped drive the company's overall growth from a 20 person start-up to a global 1,200+ employee research, development and commercial enterprise over 9 years. Developed and was responsible for bluebird's severe genetic disease franchise and oncology franchise strategies as well as the overall corporate development strategy including the foundational deal with Celgene/BMS which led to the discovery of Ide-cell (Abecma). Led BLUE's initial public offering in 2013 and subsequent equity financings, totaling over $3 billion. - Active member of the Board of Directors of several biotech companies: Tevard Biosciences and Tenaya Therapeutics (TNYA - Audit Chair and Comp Committee). - Former member of the Board of Directors (Executive Committee Member and Treasurer) of ARM (the Alliance for Regenerative Medicine). - Former chief business officer of Taligen Therapeutics leading the financial management, commercial development and business development of the company. Played a key role in the growth of the company as well as the sale of Taligen to Alexion Pharmaceuticals in January 2011. - Previously held senior level business development, finance, strategic planning and operations roles at Allscripts (MDRX), PathoGenesis (PGNS sold to Chiron for $700 million), EXACT Sciences (EXAS) and Inotek Pharmaceuticals. - Started career at SmithKline Beecham in finance, worldwide business development and managed care contracting roles. - Received M.B.A. from the Kellogg Graduate School of Management at Northwestern University and B.A. from Yale University. Specialties: Strategy, Financial Management, M&A, Business Development, Legal, Business Operations, Fund Raising, Commercial Development & Culture Building